Guardant Health, Inc. (GH): Results of Operations and Financial Condition
Guardant Health, Inc. (GH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gh-06302026xexhibit991.htm EX-99.1 Document Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to
How this was made
The 30-second read
Why it matters
The filing provides fresh, decision-relevant numbers: Q2 revenue growth, updated full-year revenue and segment growth assumptions, margin outlook, and free cash flow burn range, plus new FDA approvals and Shield coverage/guideline inclusion that can drive incremental demand.
Market read
A same-day 8-K with raised guidance and multiple adoption catalysts typically drives repricing of growth and adoption curves for liquid biopsy and screening franchises.
What to watch
Traders may scrutinize whether the higher Shield volume and lab capacity investments compress margins or extend cash burn beyond the updated $195M to $205M outlook.
Background
SEC Form 8-K Item 2.02 reporting Guardant Health’s Q2 2026 financial results and updated 2026 guidance, alongside FDA and commercial adoption milestones.
Ticker impact
Guardant reported Q2 2026 revenue of $335.0M (+44% YoY) and raised 2026 revenue guidance to $1.34 to $1.36B (+36% to 38%).
Near-term bias higher as traders price the raised 2026 revenue and Shield volume outlook; follow-through depends on whether margins and cash burn trajectory stabilizes.
Guidance midpoint rises versus prior range, Shield test volume guidance is increased, and the filing includes fresh FDA approvals and insurer coverage, all of which are direct demand and adoption drivers.
Market effects
Supports sentiment for precision oncology and liquid biopsy adoption, especially colorectal screening and companion diagnostic expansion.
Primarily US-focused adoption signals (FDA approvals, US insurer coverage, ACS guideline inclusion) may influence US biotech tape.
Companion diagnostic approval tied to a specific therapy can strengthen global commercial confidence, though the filing is US-centric.
Counterpoint
Despite revenue growth, the company still reports large net losses and free cash flow burn, and operating expenses are rising faster than revenue.
Key entities
- companyGuardant Health, Inc.
Precision oncology company reporting Q2 2026 results and raising 2026 revenue guidance; highlights FDA approvals and Shield screening adoption.
- regulatorU.S. Food and Drug Administration (FDA)
Approved Guardant360 Liquid CDx and Guardant360 CDx as a companion diagnostic for HERNEXEOS (HER2-mutant advanced NSCLC).
- commercial_partnerUnitedHealth Group
Provided Shield coverage, described as the first major commercial insurer to cover the test.
- guideline_bodyAmerican Cancer Society (ACS)
Updated colorectal cancer screening guidelines to include Shield.
- partnerBoehringer Ingelheim
HERNEXEOS is referenced as the therapy for which Guardant360 CDx is approved as a companion diagnostic.
